These data suggest that the lethal pancreatic cancer can indeed be inhibited in vivo with very significant survival outcomes and a safe profile by 3′UTRMYC1-18, thus serving a strong rationale for acceleration of the novel c-MYC-mRNA drug toward a phase 1 trial in humans with diverse c-MYC-driven cancers, including lethal pancreatic cancers of all stages. This evidence concerns the gene MYC and familial pancreatic carcinoma.